• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Midatech Pharma PLC American Depositary Shs

    12/29/23 12:10:19 PM ET
    $MTP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTP alert in real time by email
    6-K 1 f6k_122923.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of December 2023

    Commission File Number: 001-37652

    Biodexa Pharmaceuticals PLC
    (Translation of registrant's name into English)

    1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom
    (Address of principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F [ X ]      Form 40-F [   ]

    The information included in this report on Form 6-K, excluding Exhibit 99.1 attached hereto, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333-267932) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit 99.1 to this Report is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.


     

    Appointment of Director

     

    On December 13, 2023, the Board of Directors (the “Board”) of Biodexa Pharmaceuticals PLC (the “Company”) appointed Ann Merchant as a director, effective December 31, 2023. Ms. Merchant shall serve for a term to expire at the Company’s annual general meeting in 2026. A copy of the press release announcing the appointment is attached hereto and furnished as Exhibit 99.1.

     

    Ms. Merchant, aged 58, has served as Vice President for MorphoSys AG (NASDAQ: MOR), a commercial stage biopharmaceutical company headquartered in Munich, Germany, since 2018, and as Head of Global Supply Chain and External Operations since January 2019. From September 2011 to August 2018, Ms. Merchant served as the President for Schreiner Medipharm, a business unit of the Schreimer Group Gmbh & Co. KG. Between 1994 and 2011, Ms. Merchant held various roles at Amgen Inc. (NASDAQ: AMGN), including Vice President, Head of International Supply Chain and Site Head between 2007 and 2011. Ms. Merchant currently serves on the board of directors of Alvotech S.A. (NASDAQ: ALVO), a biosimilar company. Ms. Merchant holds an MBA from the Henley Business School and a Bachelor of Science in Languages from Georgetown University.

     

    Ms. Merchant will be entitled to standard compensation paid by the Company to its non-executive directors. Further, in connection with Ms. Merchant’s appointment, the Company expects to grant to Ms. Merchant options to acquire one percent of the Company’s outstanding ordinary shares.

     

    The Company expects to appoint Ms. Merchant to serve on the audit committee and the remuneration committee.

     

    There are no arrangements or understandings between Ms. Merchant and any other person pursuant to which she was appointed as a director of the Company. There are no transactions between Ms. Merchant and the Company that would be reportable pursuant to Form 20-F. Ms. Merchant has not previously held any positions with the Company and has no family relations with any directors or executive officers of the Company.

     


    SUBMITTED HEREWITH

    Attached to the Registrant’s Form 6-K filing for the month of December 2023, and incorporated by reference herein, is:  

    Exhibit No.   Description
         
    99.1   Press Release dated December 29, 2023


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

            Biodexa Pharmaceuticals PLC    
        (Registrant)
         
       
    Date: December 29, 2023       /s/ Stephen Stamp    
        Stephen Stamp
        Chief Executive Officer, Chief Financial Officer
       

      

     

    Get the next $MTP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease

      ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.BackgroundMany cancers exhibit high levels of metabolic plasticity, i.e. the ability to switch between energy-generating pathways in response to cellular stresses[1], such as those caused by chemotherapy. Highly proliferative cancers frequently use the aerobic glycolysis pathway, known as "the Warburg effect", to generate energy2. Oxidat

      3/27/23 8:20:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Results of General Meeting

      Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 24, 2023 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed.The full text of, inter alia, the resolutions proposed and passed at the General Meeting can be found in the Company's Shareholder Circular and Notice of General Meeting (the "Circular") which

      3/24/23 8:00:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Further re: Notice of General Meeting

      Midatech Pharma PLC ("Midatech" or the "Company") Further re: Notice of General Meeting - Correction of Typographical ErrorsABINGDON, OXFORDSHIRE / ACCESSWIRE / March 10, 2023 / Further to the announcement made on 8 March 2023 providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "Notice") and form of proxy (the "Form of Proxy"), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:· Resolution 4 of the Notice ("Resolution 4") refers to a proposed aut

      3/10/23 1:45:00 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Financials

    Live finance-specific insights

    See more
    • Midatech Pharma PLC Announces Posting of Circular and Notice of General Meeting

      Proposed Share Consolidation, Authority to Allot Shares, Disapplication of Pre-Emption Rights, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 8, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces, further to the Company's announcements of 9 February and 15 February 2023, that a circular (the "Circular") and formal Notice of General Meeting was posted to shareholders yesterday and will be made available on the Company's website at: www.midatechpharma.com/investors/shareholder-information.The

      3/8/23 2:20:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 8:47:28 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 2:42:24 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 2:14:48 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    SEC Filings

    See more
    • SEC Form 6-K filed by Midatech Pharma PLC American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      1/22/24 8:51:48 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Midatech Pharma PLC American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      12/29/23 12:10:19 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Midatech Pharma PLC American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      12/26/23 4:53:52 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Leadership Updates

    Live Leadership Updates

    See more
    • Midatech Pharma PLC Announces Appointment of Nominated and Financial Adviser

      ABINGDON, UK / ACCESSWIRE / March 8, 2022 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, is pleased to announce the appointment of Strand Hanson Limited as the Company's Nominated and Financial Adviser with immediate effect.Turner Pope Investments (TPI) Ltd will be the Company's sole broker.For further information, please contact:Midatech Pharma PLCStephen Stamp, CEO, CFOTel: +44 (0) 29 2048 0180www.midatechpharma.com Strand Hanson Limited (Nominated and Financial Adviser)James Dance / Matthew Chandler / Rob PatrickTel: +44 (0)20 7409 3494 Turner Pope Investments (TPI) Ltd (Broker)Andre

      3/8/22 5:00:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Appointment of Chief Scientific Officer

      Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific OfficerABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12, 2021 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect.Dr. Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA. Most recently, he was Chief Medical Offic

      7/12/21 9:50:00 AM ET
      $MTP
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care